Executives of EpiPen maker Mylan NV are unlikely to suffer a
reduction in their pay from the company's recent $465 million
settlement of allegations that it improperly overcharged Medicaid
for the lifesaving drug.
That is because Mylan historically has calculated executive pay
using a nonstandard measure called "adjusted diluted" earnings,
which excludes the costs of such litigation settlements, the
company's regulatory filings show.
The settlement with the federal government, announced by Mylan
earlier this month but not yet finalized, comes amid continuing
public and congressional scrutiny of Mylan over steep price
increases on EpiPen, its treatment for severe allergic reactions,
and the separate but related issue of its Medicaid charges for the
drug.
The cost of the Medicaid settlement is substantial for
Mylan—more than double the company's pretax earnings for the first
six months of 2016.
Mylan declined to comment. The company previously said the
settlement with the government included no finding of any
wrongdoing on the part of the company or any employees.
Mylan recently gave updated earnings guidance that made it clear
the $465 million expense wouldn't figure into its adjusted diluted
earnings for this year.
Numerous companies, including many of Mylan's drug-industry
peers, also calculate executive pay using nonstandard earnings
measures.
About 400 companies in the S&P 500 reported a form of
adjusted net income in 2015, and just over a quarter of them
omitted legal charges and gains, according to an analysis by Jack
Ciesielski, publisher of Analyst's Accounting Observer.
But some shareholders say Mylan CEO Heather Bresch and other
executives—already among the highest-paid in the drug
industry—shouldn't be insulated from the EpiPen Medicaid
imbroglio.
"It would be grossly inappropriate for Mylan to exclude the cost
of this penalty when determining incentive pay for top executives,"
said New York City Comptroller Scott Stringer, who oversees pension
funds holding more than one million Mylan shares. "The executives
enjoyed lucrative payouts in the past for performance that turns
out to have been based on improper conduct, and the company and its
shareowners are now suffering the consequences."
Counting the settlement cost would cut about 12% off adjusted
earnings this year, estimated Ronny Gal, an analyst with Sanford C.
Bernstein. That could put a crimp in the paycheck of Ms. Bresch,
who earned $18.9 million last year, of which $3.9 million was a
bonus based in large part on adjusted earnings performance.
Late Wednesday, Sen. Charles Grassley (R., Iowa), said that his
Senate Judiciary Committee would hold a Nov. 30 hearing on Mylan's
Medicaid settlement, saying, "Americans deserve to know what the
government is doing to hold Mylan accountable, recoup lost tax
dollars and prevent similar behavior in the future."
Mylan's settlement comes after senators and federal health
officials alleged the company wrongly classified EpiPen as a
generic for the purposes of figuring rebates owed to Medicaid, even
though it is considered a brand-name drug by the Food and Drug
Administration.
That let Mylan have it both ways: The company could reap large
profits from the patent-protected drug in the broader marketplace,
while paying rebates to Medicaid at a substantially reduced generic
rate. Medicaid, a health program for low-income individuals, is
funded jointly by states and the federal government.
Federal health officials have said they "expressly told Mylan
that the product is incorrectly classified" as a generic, although
when that warning was made is unclear.
In announcing the settlement, Mylan said it had classified the
drug as a generic "based on longstanding written guidance from the
federal government" dating to before Mylan acquired EpiPen in
2007.
Over the past five years, Mylan's "adjusted diluted" earnings
have averaged 85% higher than its earnings reported under generally
accepted accounting principles, filings show. In the first half of
this year, adjusted earnings were five times GAAP earnings of 36
cents per share.
Mylan's top executives were paid nearly $300 million in
aggregate over the past five years, second highest for the drug
industry.
Earnings adjustments for executive pay are spreading. More than
half the companies in the S&P 500 cited "non-GAAP" results in
their proxies this year, up from 27% five years ago, research firm
Audit Analytics found this spring.
Across the S&P 500, adjustments increased reported earnings
by 42% in 2015, or 20% excluding the volatile energy sector, Mr.
Ciesielski said.
There is nothing improper about this, as long as the metrics are
adequately disclosed. And some specialists favor adjusting results
to determine pay, eliminating nonrecurring or unusual costs,
because shareholders want to tie incentives to ongoing
operations.
Boards can change incentive formulas and typically have
discretion to reduce pay below formulaic results, said Steven Hall,
managing director of compensation consultancy Steven Hall &
Partners. "In the majority of the cases I see, the board has the
ability to say, 'Stop, you don't deserve this.' "
Companies can also seek to recoup earlier pay, as Wells Fargo
& Co. did before its CEO's recent departure amid controversy
over the bank's sales practices, though that is rare.
Mylan has a limited clawback policy that applies only in the
event of "misconduct that causes Mylan to materially restate its
financial statements."
Write to Mark Maremont at mark.maremont@wsj.com and Theo Francis
at theo.francis@wsj.com
(END) Dow Jones Newswires
October 27, 2016 07:55 ET (11:55 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Apr 2024 to May 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From May 2023 to May 2024